AVAC Comments to FDA in Support of PrEP Approval

Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.

Topics:

Accelerating Product Innovation

Advocating for Health Equity